The enzyme dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagon-like peptide-1 (GLP-1). Since GLP-1-based ... both have a long duration of action, allowing once-daily administration.

The risks for disease progression and death were lower for patients with stage 3b or higher CKD receiving GLP-1 RA vs DPP4i ... dipeptidyl peptidase-4 inhibitors (DPP-4i) in male patients with ...

Metabolic control can be improved markedly by administration of exogenous GLP-1, but the ... that inhibit DPP-4, thereby prolonging the duration of endogenous incretin action, have, therefore ...

Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term.

The researchers reviewed 601 published trials of older people to investigate whether the efficacy of three medications — DPP-4 inhibitors, SGLT2 inhibitors, and GLP-1 agonists — was affected ...

"GLP-1 also tells the brain that there's fluid in the gastrointestinal tract, so you should start feeling full and stop ...

Scientists may have found a way to help the body naturally produce more of an Ozempic-like hormone, to curb sugar cravings and improve metabolic health. Glucagon-like peptide-1 (GLP-1) is a ...

GLP-1 drugs currently available for weight loss ... s drug a dosing edge over many of the potential next-generation metabolic medications in development as once-daily pills. On Thursday, the ...

Treatment with any class of therapy was associated with an HbA1c reduction of 0.5 to 1.5 percentage points compared with placebo. SGLT2 inhibitors and GLP-1s, but not DPP-IV inhibitors ...